These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29854151)

  • 1. Comparing and Contrasting A Priori and A Posteriori Generalizability Assessment of Clinical Trials on Type 2 Diabetes Mellitus.
    He Z; Gonzalez-Izquierdo A; Denaxas S; Sura A; Guo Y; Hogan WR; Shenkman E; Bian J
    AMIA Annu Symp Proc; 2017; 2017():849-858. PubMed ID: 29854151
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Trial Generalizability Assessment in the Big Data Era: A Review.
    He Z; Tang X; Yang X; Guo Y; George TJ; Charness N; Quan Hem KB; Hogan W; Bian J
    Clin Transl Sci; 2020 Jul; 13(4):675-684. PubMed ID: 32058639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A distribution-based method for assessing the differences between clinical trial target populations and patient populations in electronic health records.
    Weng C; Li Y; Ryan P; Zhang Y; Liu F; Gao J; Bigger JT; Hripcsak G
    Appl Clin Inform; 2014; 5(2):463-79. PubMed ID: 25024761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlating eligibility criteria generalizability and adverse events using Big Data for patients and clinical trials.
    Sen A; Ryan PB; Goldstein A; Chakrabarti S; Wang S; Koski E; Weng C
    Ann N Y Acad Sci; 2017 Jan; 1387(1):34-43. PubMed ID: 27598694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Framework for Systematic Assessment of Clinical Trial Population Representativeness Using Electronic Health Records Data.
    Sun Y; Butler A; Diallo I; Kim JH; Ta C; Rogers JR; Liu H; Weng C
    Appl Clin Inform; 2021 Aug; 12(4):816-825. PubMed ID: 34496418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessing the Validity of a
    Li Q; He Z; Guo Y; Zhang H; George TJ; Hogan W; Charness N; Bian J
    AMIA Annu Symp Proc; 2019; 2019():1101-1110. PubMed ID: 32308907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the representativeness and generalizability of Japanese clinical trials for localized rectal/colon cancer: Comparing participants in the Japan Clinical Oncology Group study with patients in Japanese registries.
    Miyamoto K; Wakabayashi M; Mizusawa J; Nakamura K; Katayama H; Higashi T; Inomata M; Kitano S; Fujita S; Kanemitsu Y; Fukuda H
    Eur J Surg Oncol; 2020 Sep; 46(9):1642-1648. PubMed ID: 32340817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Contemporary use of real-world data for clinical trial conduct in the United States: a scoping review.
    Rogers JR; Lee J; Zhou Z; Cheung YK; Hripcsak G; Weng C
    J Am Med Inform Assoc; 2021 Jan; 28(1):144-154. PubMed ID: 33164065
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical comparison between trial participants and potentially eligible patients using electronic health record data: A generalizability assessment method.
    Rogers JR; Hripcsak G; Cheung YK; Weng C
    J Biomed Inform; 2021 Jul; 119():103822. PubMed ID: 34044156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conformity between protocol eligibility criteria for electronic patient identification: a comparison of clinical trials.
    Kamauu A; Agbor S; Kamauu A
    Stud Health Technol Inform; 2013; 192():1167. PubMed ID: 23920941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Using Real-World Data to Rationalize Clinical Trials Eligibility Criteria Design: A Case Study of Alzheimer's Disease Trials.
    Li Q; Guo Y; He Z; Zhang H; George TJ; Bian J
    AMIA Annu Symp Proc; 2020; 2020():717-726. PubMed ID: 33936446
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Leveraging Real-World Data for the Selection of Relevant Eligibility Criteria for the Implementation of Electronic Recruitment Support in Clinical Trials.
    Melzer G; Maiwald T; Prokosch HU; Ganslandt T
    Appl Clin Inform; 2021 Jan; 12(1):17-26. PubMed ID: 33440429
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Defining Clinically Relevant Target Populations Using Real-World Data to Guide the Design of Representative Antidiabetic Drug Trials.
    Pradhan R; Abrahami D; Yin H; Yu OHY; Sahasrabudhe V; Baumfeld Andre E; Azoulay L
    Clin Pharmacol Ther; 2021 May; 109(5):1219-1223. PubMed ID: 33615445
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eligibility criteria for HIV clinical trials and generalizability of results: the gap between published reports and study protocols.
    Gandhi M; Ameli N; Bacchetti P; Sharp GB; French AL; Young M; Gange SJ; Anastos K; Holman S; Levine A; Greenblatt RM
    AIDS; 2005 Nov; 19(16):1885-96. PubMed ID: 16227797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Computer-aided assessment of the generalizability of clinical trial results.
    Cahan A; Cahan S; Cimino JJ
    Int J Med Inform; 2017 Mar; 99():60-66. PubMed ID: 28118923
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generalizability of Cardiovascular Safety Trials on SGLT2 Inhibitors to the Real World: Implications for Clinical Practice.
    Nicolucci A; Candido R; Cucinotta D; Graziano G; Rocca A; Rossi MC; Tuccinardi F; Manicardi V
    Adv Ther; 2019 Oct; 36(10):2895-2909. PubMed ID: 31410779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating eligibility criteria of oncology trials using real-world data and AI.
    Liu R; Rizzo S; Whipple S; Pal N; Pineda AL; Lu M; Arnieri B; Lu Y; Capra W; Copping R; Zou J
    Nature; 2021 Apr; 592(7855):629-633. PubMed ID: 33828294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular risk profiles: A cross-sectional study evaluating the generalizability of the glucagon-like peptide-1 receptor agonist cardiovascular outcome trials REWIND, LEADER and SUSTAIN-6 to the real-world type 2 diabetes population in the United Kingdom.
    Webb J; Mount J; von Arx LB; Rachman J; Spanopoulos D; Wood R; Tritton T; Massey O; Idris I
    Diabetes Obes Metab; 2022 Feb; 24(2):289-295. PubMed ID: 34668637
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ClinicalTrials.gov as a data source for semi-automated point-of-care trial eligibility screening.
    Pfiffner PB; Oh J; Miller TA; Mandl KD
    PLoS One; 2014; 9(10):e111055. PubMed ID: 25334031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.